Medications for opioid use disorder: bridging the gap in care.

CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016

Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161 · see citing works

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697 · see citing works

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312 · see citing works

Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis

Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., & Ozonoff, A. (2013) · BMJ · doi:10.1136/bmj.f174 · Cited by 999 · see citing works

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700 · see citing works

The Role of Science in Addressing the Opioid Crisis

Volkow, N. D., & Collins, F. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmsr1706626 · Cited by 557 · see citing works

Maintenance Medication for Opiate Addiction: The Foundation of Recovery

Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461 · see citing works

County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States

Handel, M. M. V., Rose, C. E., Hallisey, E. J., Kolling, J., Zibbell, J. E., Lewis, B. E., Bohm, M. K., Jones, C. M., Flanagan, B. E., Siddiqi, A.-E.-A., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001098 · Cited by 439 · see citing works

Oral naltrexone maintenance treatment for opioid dependence

Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001333.pub4 · Cited by 432 · see citing works

Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid–Involved Overdose Deaths — 27 States, 2013–2014

Gladden, R. M., Martínez, P. D., & Seth, P. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6533a2 · Cited by 426 · see citing works

CDC guideline for prescribing opioids for chronic pain

Haegerich, T. M., Dowell, D., & Tauben, D. J. (2016) · Cited by 330 · see citing works

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial

Tanum, L., Solli, K. K., Latif, Z.-E.-H., Benth, J. Š., Opheim, A., Sharma-Haase, K., Krajci, P., & Kunøe, N. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3206 · Cited by 253 · see citing works

Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds

Whelan, P., & Remski, K. (2012) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.91934 · Cited by 208 · see citing works

Comparing overdose mortality associated with methadone and buprenorphine treatment

Bell, J. R., Butler, B., Lawrance, A., Batey, R. G., & Salmelainen, P. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.03.020 · Cited by 180 · see citing works

Update on Barriers to Pharmacotherapy for Opioid Use Disorders

Sharma, A., Kelly, S. M., Mitchell, S. G., Gryczynski, J., O’Grady, K. E., & Schwartz, R. P. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0783-9 · Cited by 163 · see citing works

Impact of treatment for opioid dependence on fatal drug‐related poisoning: a national cohort study in England

Pierce, M., Bird, S. M., Hickman, M., Marsden, J., Dunn, G., Jones, A., & Millar, T. (2015) · Addiction · doi:10.1111/add.13193 · Cited by 155 · see citing works

Increased use of heroin as an initiating opioid of abuse

Cicero, T. J., Ellis, M. S., & Kasper, Z. A. (2017) · Addictive Behaviors · doi:10.1016/j.addbeh.2017.05.030 · Cited by 153 · see citing works

Oral naltrexone maintenance treatment for opioid dependence

Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001333.pub3 · Cited by 151 · see citing works

Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone

Rosado, J., WALSH, S. L., Bigelow, G. E., & Strain, E. C. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.04.006 · Cited by 97 · see citing works

Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment

Brown, J. D., Goodin, A. J., & Talbert, J. (2017) · The Journal of Rural Health · doi:10.1111/jrh.12251 · Cited by 95 · see citing works

“I Kicked the Hard Way. I Got Incarcerated.” Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments

Maradiaga, J., Nahvi, S., Cunningham, C. O., Sanchez, J., & Fox, A. D. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.11.004 · Cited by 59 · see citing works

Just call it “treatment”

Friedmann, P. D., & Schwartz, R. P. (2012) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-7-10 · Cited by 52 · see citing works

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX)

Nunes, E. V., Krupitsky, E. M., Ling, W. W., Zummo, J., Memisoglu, A., Silverman, B. L., & Gastfriend, D. R. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000125 · Cited by 46 · see citing works

To Battle The Opioid Overdose Epidemic, Deploy The ‘Cascade Of Care’ Model

Williams, A. R., Nunes, E. V., & Olfson, M. (2017) · doi:10.7916/d8rx9qf3 · Cited by 37 · see citing works

Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence

Kjome, K. L., & Moeller, F. G. (2011) · Substance Abuse Research and Treatment · doi:10.4137/sart.s5452 · Cited by 34 · see citing works

To Battle The Opioid Overdose Epidemic, Deploy The ‘Cascade of Care’ Model

(2017) · Forefront Group · doi:10.1377/forefront.20170313.059163 · Cited by 18 · see citing works

Fentanyl: China's Deadly Export to the United States

O’Connor, S. D. (2017) · Cited by 16 · see citing works

Global patterns of opioid use and dependence: harms to populations, interventions, and future action

Degenhardt, L. J., Grebely, J., Stone, J., Hickman, M., Vickerman, P. T., Marshall, B. D. L., Bruneau, J., Altice, F. L., Henderson, G., Rahimi‐Movaghar, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32229-9 · Cited by 853 · see citing works

Smartphone Apps Targeting Alcohol and Illicit Substance Use: Systematic Search in in Commercial App Stores and Critical Content Analysis

Tofighi, B., Chemi, C., Ruiz-Valcarcel, J., Hein, P. N., & Hu, L. (2018) · JMIR mhealth and uhealth · doi:10.2196/11831 · Cited by 129 · see citing works

Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: An observational analysis

Baldwin, N., Gray, R., Goel, A., Wood, E., Buxton, J. A., & Rieb, L. M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.12.032 · Cited by 83 · see citing works

Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder

Carroll, K. M., Nich, C., Frankforter, T. L., Yip, S. W., Kiluk, B. D., DeVito, E. E., & Sofuoglu, M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.08.019 · Cited by 73 · see citing works

Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder

Kiluk, B. D., Yip, S. W., DeVito, E. E., Carroll, K. M., & Sofuoglu, M. (2019) · Clinical Psychological Science · doi:10.1177/2167702619855659 · Cited by 63 · see citing works

Drug Interactions With New Synthetic Opioids

Pérez‐Mañá, C., Papaseit, E., Fonseca, F., Farré, A., Torrens, M., & Farré, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01145 · Cited by 60 · see citing works

Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT‐SMS)

Smith, L. R., Mittal, M. L., Wagner, K. D., Copenhaver, M. M., Cunningham, C. O., & Earnshaw, V. A. (2019) · Addiction · doi:10.1111/add.14799 · Cited by 53 · see citing works

Randomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for Use in Office-Based Buprenorphine Maintenance

Shi, J. M., Henry, S., Dwy, S. L., Orazietti, S. A., & Carroll, K. M. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1569192 · Cited by 43 · see citing works

Chronic heroin use disorder and the brain: Current evidence and future implications

Tolomeo, S., Steele, J. D., Ekhtiari, H., & Baldacchino, A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110148 · Cited by 38 · see citing works

Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment

Yedinak, J. L., Goedel, W. C., Paull, K., Lebeau, R., Krieger, M. S., Thompson, C., Buchanan, A. L., Coderre, T., Boss, R., Rich, J. D., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002963 · Cited by 35 · see citing works

The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder

Friesen, E. L., & Kurdyak, P. A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108244 · Cited by 35 · see citing works

Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys

Kohut, S. J., & Bergman, J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.025 · Cited by 33 · see citing works

Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder

Brandt, L., Jones, J. D., Martinez, S., Manubay, J. M., Mogali, S., Ramey, T., LEVIN, F. R., & Comer, S. D. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107859 · Cited by 33 · see citing works

Enhancing analgesic spinal cord stimulation for chronic pain with personalized immersive virtual reality

Solcà, M., Krishna, V., Young, N. A., Deogaonkar, M. S., Herbelin, B., Orepić, P., Mange, R., Rognini, G., Serino, A., Rezai, A. R., et al. (2020) · Pain · doi:10.1097/j.pain.0000000000002160 · Cited by 32 · see citing works

Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York

Neighbors, C. J., Choi, S., Healy, S., Yerneni, R., Sun, T., & Shapoval, L. (2019) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-019-0215-4 · Cited by 30 · see citing works

Interventions for Hospitalized Medical and Surgical Patients with Opioid use Disorder: A Systematic Review

French, R., Aronowitz, S. V., Carthon, J. M. B., Schmidt, H. D., & Compton, P. A. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1949663 · Cited by 30 · see citing works

Data Needs in Opioid Systems Modeling: Challenges and Future Directions

Jalali, M. S., Ewing, E. G., Bannister, C. B., Glos, L. J., Eggers, S. L., Lim, T. Y., Stringfellow, E. J., Stafford, C. A., Pacula, R. L., Jalal, H. J., et al. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2020.08.017 · Cited by 29 · see citing works

Acceptability and efficacy of naltrexone for criminal justice‐involved individuals with opioid use disorder: a systematic review and meta‐analysis

Bahji, A., Carlone, D., & Altomare, J. (2019) · Addiction · doi:10.1111/add.14946 · Cited by 27 · see citing works

Extended‐release naltrexone (XR‐NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry

Saxon, A. J., Akerman, S. C., Liu, C., Sullivan, M. A., Silverman, B. L., & Vocci, F. J. (2018) · Addiction · doi:10.1111/add.14199 · Cited by 26 · see citing works

Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients

Herscher, M., Fine, M., Navalurkar, R., Hirt, L., & Wang, L. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.003 · Cited by 26 · see citing works

Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities

Park, K., & Otte, A. (2019) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-060418-052155 · Cited by 26 · see citing works

Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service

Nordeck, C. D., Welsh, C., Schwartz, R. P., Mitchell, S. G., O’Grady, K. E., & Gryczynski, J. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100031 · Cited by 25 · see citing works

Influence of improved behavioral inhibition on decreased cue-induced craving in heroin use disorder: A preliminary intermittent theta burst stimulation study

Kang, T., Ding, X., Zhao, J., Li, X., Xie, R., Jiang, H., He, L., Hu, Y., Liang, J., Zhou, G., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.06.010 · Cited by 25 · see citing works

Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic

Miles, J., Howell, J., Sheridan, D., Braucht, G. S., & Mericle, A. A. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1719410 · Cited by 23 · see citing works

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder

Flam-Ross, J. M., Marsh, E., Weitz, M., Savinkina, A., Schackman, B. R., Wang, J., Madushani, R. W. M. A., Morgan, J. R., Barocas, J. A., Walley, A. Y., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29583 · Cited by 21 · see citing works

Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome

Dunn, K. E., Bergeria, C. L., Huhn, A. S., & Strain, E. C. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108212 · Cited by 22 · see citing works

Integrating addiction medicine into rural primary care: Strategies and initial outcomes.

Logan, D. E., Lavoie, A. M., Zwick, W. R., Kunz, K., Bumgardner, M. A., & Molina, Y. (2019) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000410 · Cited by 21 · see citing works

Emergency department patients with untreated opioid use disorder: A comparison of those seeking versus not seeking referral to substance use treatment

Coupet, E., D’Onofrio, G., Chawarski, M. C., Edelman, E. J., O’Connor, P. G., Owens, P. H., Martel, S. H., Fiellin, D. A., Cowan, E. A., Richardson, L. D., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108428 · Cited by 19 · see citing works

Modeling the Dynamics of Heroin and Illicit Opioid Use Disorder, Treatment, and Recovery

Cole, S., & Wirkus, S. A. (2022) · Bulletin of Mathematical Biology · doi:10.1007/s11538-022-01002-w · Cited by 18 · see citing works

Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic

Balestra, S., Liebert, H., Maestas, N., & Sherry, T. B. (2021) · National Bureau of Economic Research · doi:10.3386/w29596 · Cited by 17 · see citing works

Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone

Ruglass, L. M., Scodes, J. M., Pavlicová, M., Campbell, A. N. C., Fitzpatrick, S., Barbosa‐Leiker, C., Burlew, A. K., Greenfield, S. F., Rotrosen, J., & Nunes, E. V. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107649 · Cited by 16 · see citing works

Understanding the use of telemedicine across different opioid use disorder treatment models: A scoping review

Teck, J. T. W., Butner, J. L., & Baldacchino, A. (2023) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x231195607 · Cited by 15 · see citing works

A review of the kappa opioid receptor system in opioid use

Çayır, S., Zhornitsky, S., Barzegary, A., Carreño, E. S., Sarfo-Ansah, W., Funaro, M. C., Matuskey, D., & Angarita, G. A. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105713 · Cited by 13 · see citing works

Functional Correlates of Resting-State Connectivity in the Default Mode Network of Heroin Users on Methadone Treatment and Medication-Free Therapeutic Community Program

Kuo, L., Lin, P.-S., Lin, S.-Y., Liu, M.-F., Jan, H., Lee, H., & Wang, S.-C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00381 · Cited by 13 · see citing works

Physicians’ satisfaction with providing buprenorphine treatment

Knudsen, H. K., Brown, R., Jacobson, N. A., Horst, J., Kim, J., Collier, E., Starr, S., Madden, L. M., Haram, E., Toy, A., et al. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0163-3 · Cited by 10 · see citing works

Global research production in neonatal abstinence syndrome: A bibliometric analysis

Zyoud, S. H., Al‐Jabi, S. W., Shahwan, M. J., & Jairoun, A. A. (2022) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v11.i3.307 · Cited by 9 · see citing works

Re-socializing the Vulnerable Brain: Building an Ethically Sustainable Brain Disease Model of Addiction

Kuorikoski, J., & Uusitalo, S. (2018) · Frontiers in Sociology · doi:10.3389/fsoc.2018.00039 · Cited by 7 · see citing works

Within-subject evaluation of interim buprenorphine treatment during waitlist delays

Oleskowicz, T. N., Ochalek, T. A., Peck, K. R., Badger, G. J., & Sigmon, S. C. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108532 · Cited by 6 · see citing works

Fewer Than 1 In 3 Adolescents With Past-Year Opioid Use Disorder Received Substance Use Treatment, 2022–23

Cano, M. N., Hernandez, N., Mendoza, N. S., & Bagley, S. M. (2025) · Health Affairs · doi:10.1377/hlthaff.2025.00240 · Cited by 5 · see citing works

The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial

Bahji, A., Bastien, G., Bach, P., Choi, J., Foll, B. L., Lim, R., Jutras‐Aswad, D., & Socias, M. E. (2023) · The Canadian Journal of Psychiatry · doi:10.1177/07067437231194385 · Cited by 4 · see citing works

Shortages of Medication-Assisted Treatment for Opioid Use Disorder in Underserved Michigan Counties: Examining the Influence of Urbanicity and Income Level

Lister, J. J., Weaver, A., Ellis, J. D., Molfenter, T. D., Ledgerwood, D. M., & Himle, J. A. (2020) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2020.0095 · Cited by 5 · see citing works

Evidence-Based Practices or Practice-Based Evidence: What Is the Future?

Horvitz-Lennon, M. V. (2019) · Springer eBooks · doi:10.1007/978-3-030-11908-9_21 · Cited by 5 · see citing works

Perioperative Management and Analgesia for Patients Taking Buprenorphine and Other Forms of Medication-Assisted Treatment for Substance Abuse Disorders

Scholzen, E. A., Zeng, A. M., & Schroeder, K. M. (2019) · Advances in Anesthesia · doi:10.1016/j.aan.2019.08.002 · Cited by 5 · see citing works

How Would You Treat This Patient With Acute and Chronic Pain From Sickle Cell Disease?

Kanjee, Z., Achebe, M., Smith, W. R., & Burns, R. B. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0038 · Cited by 4 · see citing works

Laws Forbidding Pregnancy Discrimination in Substance Use Disorder Treatment Are Not Associated With Treatment Access

Davis, C. S., McNeer, E. A., & Patrick, S. W. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000897 · Cited by 4 · see citing works

Bio-Behavioral Indices of Emotion Regulation: Potential Targets for Treatment in Addiction

Fox, H. C., Karim, A., & Syed, S. A. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00330-y · Cited by 4 · see citing works

“The Emergency Room” in the Drug Court System: Evaluating the Opioid Intervention Court

Kahn, L. S., Hoopsick, R. A., Horrigan-Maurer, C., & Homish, G. G. (2021) · Victims & Offenders · doi:10.1080/15564886.2020.1867277 · Cited by 4 · see citing works

Exploring Culturally Based Treatment Options for Opioid Use Disorders Among American Indian and Alaska Native Adults in California

Zeledon, I., Telles, V. M., Dickerson, D. L., Johnson, C. L., Schweigman, K., West, A. E., & Soto, C. (2022) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2022.83.613 · Cited by 5 · see citing works

Behavioral Responses to Supply-Side Drug Policy During the Opioid EpidemicPreprint

Balestra, S., Liebert, H., Maestas, N., & Sherry, T. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4114797 · Cited by 4 · see citing works

Association of chronic opioid therapy and opioid use disorder with COVID-19-related hospitalization and mortality: Evidence from three health systems in the United States

Nguyen, A. P., Binswanger, I. A., Narwaney, K. J., Ford, M. A., McClure, D. L., Rinehart, D. J., Lyons, J. A., & Glanz, J. M. (2024) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2024.102832 · Cited by 3 · see citing works

The rising tide of opioid use disorder: analyzing 30 years of epidemiological trends and socioeconomic factors in the U.S

Xu, D., Li, J., & Yan, H. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04813-5 · Cited by 3 · see citing works

Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings

Sigmon, S. C., Peck, K. R., Batchelder, S. R., Badger, G. J., Heil, S. H., & Higgins, S. T. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.31910 · Cited by 4 · see citing works

Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies

Jalali, A. (2024) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2024.2350561 · Cited by 3 · see citing works

Internal and Environmental Predictors of Physician Practice Use of Screening and Medications for Opioid Use Disorders

Miller‐Rosales, C., Busch, S. H., Meara, E. R., King, A. C., D’Aunno, T. A., & Colla, C. H. (2023) · Medical Care Research and Review · doi:10.1177/10775587231162681 · Cited by 3 · see citing works

Alternative Reinforcers Enhance the Effects of Opioid Antagonists, but Not Agonists, on Oxycodone Choice Self-Administration in Nonhuman Primates

de Moura, F. B., & Kohut, S. J. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001911 · Cited by 3 · see citing works

Medications development for food-based and drug use disorders

de Moura, F. B., Kohut, S. J., & Bergman, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.04.005 · Cited by 2 · see citing works

Assessment and Management of Endocarditis Among People Who Inject Drugs in the General Hospital Setting

Suzuki, J. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180040 · Cited by 3 · see citing works

Global use and misuse of opioids

Fincham, J. E. (2018) · International Journal of Pharmacy Practice · doi:10.1111/ijpp.12446 · Cited by 3 · see citing works

Commentary on Hayes et al. (2020): The harms of opioid dose escalation in the management of chronic non‐cancer pain

Bahji, A. (2020) · Addiction · doi:10.1111/add.14965 · Cited by 3 · see citing works

Treatment of Opioid Use Disorder With Buprenorphine-Naloxone at Chainama Hills College Hospital in Lusaka, Zambia: A Case Report

Maila, B., Tsarkov, A., Petlovanyi, P., Kweku, G., & Musonda, E. (2020) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2020.2.4.413 · Cited by 2 · see citing works

The D3 receptor antagonist SR 21502 reduces cue-induced reinstatement of methamphetamine-seeking in rats

Ranaldi, R., Timken, P. D., Parasram, D. N., Ali, T., Zhang, S., Moukha‐Chafiq, O., Augelli‐Szafran, C. E., & Streicher, J. M. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137237 · Cited by 2 · see citing works

Opioid use disorder and role of yoga as an adjunct in management (OUDARYAM): Study protocol for a randomized controlled trial

Bhargav, H., Holla, B., Mahadevan, J., Jasti, N., Philip, M., Sharma, P., Vedamurthachar, A., Mehta, U. M., Varambally, S. S., Venkatasubramanian, G., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.19392.1 · Cited by 2 · see citing works

Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study

Saunders, E. C., Budney, A. J., Cavazos‐Rehg, P. A., Scherer, E. A., Bell, K. R., John, D. T., & Marsch, L. A. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209383 · Cited by 2 · see citing works

Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”

Silverman, B. L., Bloomgren, G., Jain, P., Marcopul, K., Silveira, A. C., Fratantonio, J. L., Sullivan, M. A., & Akerman, S. C. (2018) · Drug Safety · doi:10.1007/s40264-018-0691-x · Cited by 2 · see citing works

Buprenorphine use among non-hospital residential programs

Nichols, C., Baslock, D. M., & Sieger, M. L. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.112456 · Cited by 1 · see citing works

U.S. Military Veteran Perspectives on Barriers and Facilitators to Medication Treatment for Opioid Use Disorder

Wolkowicz, N. R., Musket, C. W., Sofuoglu, M., Reilly, E. D., MacLean, R. R., & Portnoy, G. A. (2025) · Substance Use & Misuse · doi:10.1080/10826084.2025.2580518 · Cited by 1 · see citing works

Decision-Making Capacity, Opioid Use Disorder, and the 3-Stage Model of Addiction

Steren, B. J., Hughes, J., & Becker, W. C. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.020 · Cited by 1 · see citing works

Prescribers’ satisfaction with delivering medications for opioid use disorder

Knudsen, H. K., Brown, R., Jacobson, N. A., Horst, J., Kim, J., Kim, H., Madden, L. M., Haram, E., & Molfenter, T. D. (2021) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-021-00413-7 · Cited by 1 · see citing works

“Because of this rotation, this is what I want to do”: Implementation and evaluation of a telehealth opioid use disorder clinical placement for nurse practitioner students

French, R., Lyons, E., Schachter, A., Treston, J., Marshall, A., Lattimer, J., Bisaga, A. M., Behar, E., & Aronowitz, S. V. (2023) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000949 · Cited by 1 · see citing works

Strong evidence indicating the effectiveness of opioid agonist treatment

Millar, T., & Webb, R. T. (2019) · The Lancet Public Health · doi:10.1016/s2468-2667(19)30100-8 · Cited by 1 · see citing works

Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012–2017

Luu, H., Slavova, S. S., Freeman, P. R., Lofwall, M. R., Browning, S. R., Slade, E., & Bush, H. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107606 · Cited by 1 · see citing works

Extended-release naltrexone overlooked in opioid use disorders guideline

Rieb, L. M. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.69411 · Cited by 1 · see citing works

Target Population: Treatment-Resistant Opioid Use Disorder and the Role of Therapeutic Communities

Kast, K. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-26273-0_6

Global research production in neonatal abstinence syndrome: A bibliometric analysis

Zyoud, S. H., Al‐Jabi, S. W., Shahwan, M. J., & Jairoun, A. A. (2022) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v11.i3.308

“Now that I'm here, I actually have the stability and the time to really think about stuff like that”: Perspectives on medications for opioid use disorder in low-threshold harm reduction housing

Chatterjee, A., Rapisarda, S. S., Silcox, J., Zaragoza, S., Summers, C., Rolles, A., Kosakowski, S., & Green, T. C. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209810

Improving access to oral health care for patients with opioid use disorder

Rosenblum, N., Lee, F. S., Singh, S., Szpak, V., Campbell, D., Prostko, S., Hujoel, P. P., Sroussi, H., & Suzuki, J. (2026) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2025.11.012

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Roberts, E., Sanderson, E., Santo, T., Hickman, M., Farrell, M., & Degenhardt, L. J. (2026) · Addiction · doi:10.1111/add.70502

Engaging veterans in the development of mobile health interventions to support medication treatment for opioid use disorder

Wolkowicz, N. R., Musket, C. W., Reilly, E. D., Kuhn, E. R., Sofuoglu, M., MacLean, R. R., & Portnoy, G. A. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1805086

A Biopsychosocial Model of Predictors of Methadone Maintenance Treatment Retention Among Iranian Men With Opioid Use Disorder

Abdollahi, E., Saberizafarghandi, M. B., Amini, M., & Hosseini‐Baharanchi, F. S. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2727593

Take-Home Messages

(2024) · doi:10.64239/pi-vl8010

Extended-release naltrexone: good but not a panacea

Lott, D. C. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32872-6 · Cited by 9 · see citing works

Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose

Harris, M. T. H., Weinstein, Z., & Walley, A. Y. (2026) · JAMA · doi:10.1001/jama.2025.26348 · Cited by 31 · see citing works

Buprenorphine

Bye, K., Juresic, S., Smith, N. T., & Siegel, L. R. (2026) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2025.11.014

Opioid Use Disorder: Medical Treatment Options.

Coffa, D. A., & Snyder, H. R. (2019) · PubMed · Cited by 55 · see citing works